The THAI-CARES RSV Study has successfully completed participant recruitment, reaching 120 children in just over nine weeks! This marks a significant milestone for the Penta-sponsored Phase II clinical trial, which is investigating the potential of remdesivir as a treatment for young children hospitalised with respiratory syncytial virus (RSV)-associated lower respiratory tract infections.
Launched in June 2025, the THAI-CARES RSV Study is focused on evaluating the safety, tolerability and efficacy of a 5-day course of remdesivir in children aged 0-2 years. It is conducted across eight clinical sites in Thailand.
The trial aims to address the global burden of RSV, a leading cause of severe respiratory illness in infants and young children, responsible for over 3 million hospitalisations annually. The study seeks to generate clinical evidence about remdesivir as a potential therapeutic option, which could improve care and outcomes for paediatric patients with RSV-related lower respiratory tract infections.
With recruitment now complete, the study team will continue with participant follow-up, data quality checks and site monitoring. Preliminary results from the trial are expected in January 2026.
This milestone was made possible through the dedication and collaboration of site principal investigators, hospital staff and study team across Thailand. We thank everyone for their commitment in reaching this important step towards advancing treatment options for children with RSV.